QIAGEN launches first FDA-approved companion diagnostic for PIK3CA biomarkers to enhance precision medicine in breast cancer

QIAGEN and U.K. alliance launch APIS Assay Technologies to expand biomarker research and foster healthcare innovation

QIAGEN’s QuantiFERON®-TB Access development program gains recognition from United Nations initiative for health innovation

QIAGEN gains 510(k) clearance by FDA for QIAstat-Dx in the U.S. and launches system as next generation platform for syndromic insights

QIAGEN and Inovio collaborate to develop companion diagnostic for novel immunotherapy targeting precancerous cervical lesions

Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052/ Share Repurchase

QIAGEN reports results for first quarter of 2019 and announces plans for new $100 million share repurchase program

Ad hoc Announcement according to Art. 17 Market Abuse Regulation

QIAGEN launches first FDA-approved companion diagnostic using FGFR alterations to help guide the treatment of metastatic urothelial cancer

QIAGEN’s QuantiFERON®-TB passes milestone of 60 million tests in global fight against tuberculosis, current annual run rate exceeds 12 million tests